Background Minimal Change Disease (MCD) is associated with CD80 expression in podocytes and elevated urinary CD80 excretion during active renal disease. We have evaluated the urinary excretion of CTLA-4 and CD80 during different stages of the nephrotic syndrome in patients with MCD to test the hypothesis that persistent increased urinary CD80 excretion in patients with MCD in relapse is due to an ineffectual CTLA-4 response of the host to curtail the activation of CD80. Methods Thirty-two children with biopsy-proven MCD were studied during relapse and/or remission. Eleven healthy subjects served as controls. Results Urinary CD80 excretion was significantly increased in MCD patients in relapse relative to that in MCD patients in remission (p<0.001) and controls (p<0.001). Although urinary CTLA-4 excretion was higher in MCD patients in relapse than in MCD patients in remission (p=0.01) and controls (p=0.03), no significant correlation was observed between urinary CD80 excretion and urinary CTLA-4 level in MCD patients at the time of relapse (p=0.06). At the time of remission, CD80 had decreased significantly in all patients, but CTLA-4 levels either decreased or remained unchanged in all but five patients, and no correlation was observed between urinary CD80 excretion and CTLA-4 level (p=0.7). Conclusions Urinary CTLA-4 levels do not correlate with urinary CD80 excretion, suggesting the possibility that the CTLA4 response may be suboptimal in this disease during relapse.
Introduction
Minimal change disease (MCD) is the most common nephrotic syndrome in childhood [1] . It is usually a relapsing disease triggered by an upper respiratory infection (URI) [2] . The relapse pattern is variable, with some patients relapsing frequently while others enjoy long periods of remission [3] .
MCD is considered to be a podocytopathy [4] . We have reported that podocytes in patients with MCD in relapse express CD80 and increase urinary excretion of this molecule in the absence of an increase in circulating soluble CD80 levels (sCD80) [5, 6] . After remission is induced, CD80 expression in podocytes remits and urinary CD80 excretion normalizes [5, 6] . Under certain circumstances, podocytes may also express CTLA-4 (cytotoxic Tlymphocyte antigen 4) [7] , which is a negative regulator of CD80 [8] . Increased CD80 expression can be facilitated by a poor CTLA-4 response [8] .
We have postulated that the persistent CD80 podocyte expression in MCD patients in relapse could be the result of an inadequate censoring of podocyte CD80 expression due to an impaired podocyte CTLA-4 response [9] . Therefore, the aim of this study was to assess the pattern of CD80 and the CTLA-4 response during different stages of the nephrotic syndrome in MCD patients. We hypothesized that intrarenal CTLA-4 production, as reflected by urinary CTLA-4 excretion, is unable to regulate podocyte CD80 expression, leading to persistently increased glomerular and urinary CD80.
Patients and methods
Patients Thirty-two children and adolescents with biopsyproven MCD, defined according to the International Study for Kidney Diseases in Children [10] , were studied (Table 1) . Twenty-three patients were studied during relapse and remission. Seven patients were studied only during relapse and two only during remission. The majority of patients with MCD in relapse and in remission were receiving variable amounts of immunosuppressive therapy. Eleven healthy subjects, aged 9-17 years, served as control ( Table 2 ). All patients and control subjects were followed at the University of Florida. The patients studied represent a different set of patients from those previously reported [6] .
This study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of Florida. Written informed consent was obtained from patients before participation. Definitions Steroid frequent relapsing patients were defined as having at least two relapses in 6 months and who at the time of relapse had not been on prednisone therapy for variable periods of time (>2 weeks) [11] . Steroid infrequent relapsing patients were defined as having one or two relapses per year. Steroid dependency was defined as the presence of two consecutive relapses during steroid therapy, or within 14 days of cessation of steroid therapy. Relapse of the nephrotic syndrome was defined as the presence of proteinuria of 3+ using the tetrabromophenolcitrate buffer colorimetric qualitative dipstick test, as confirmed by a urine protein:creatinine ratio of≥2.0 and a concomitant serum albumin level of<2.5 g/dL during the course of the episode. Complete remission was defined as no proteinuria using the colorimetric qualitative test and a urinary protein/ creatinine ratio of 0.2 on a random morning urine sample.
Methods Urinary CD80 was measured using a commercially available ELISA kit (Bender MedSystems, Burlingame, CA). We measured urinary CTLA-4 according to Oaks and Hallet with minor modifications [12] . CD80 and CTLA-4 results were adjusted for urinary creatinine excretion. Urinary creatinine and protein were measured using an autoanalyzer.
Statistical analysis Data graphics and statistical analysis were performed using Prism 5 (GraphPad Software Inc., San Diego, CA). Kruskal-Wallis tests and Mann-Whitney tests were applied to evaluate differences between the groups, and the Spearman correlation coefficient was calculated between urinary CD80 and proteinuria, urinary CTLA-4 and proteinuria, and urinary CD80 and urinary CTLA-4 at the time of relapse and remission. 
Results
Urinary CD80 excretion in MCD and control subjects Urinary CD80 excretion was significantly increased in MCD patients in relapse (464±398 ng/g creatinine) when compared to those MCD patients in remission (30±34 ng/g creatinine) (p<0.001) and control subjects (14.6±30.8 ng/g creatinine) (p<0.001) (Fig. 1a) . Twenty-four patients with MCD were studied at relapse and within 1 month after remission. Urinary CD80 decreased significantly (p<0.001) after remission was induced (Fig. 1b) . There was a positive correlation between urinary CD80 excretion and proteinuria in MCD patients in relapse (p=0.003) (Fig. 1c) Urinary CTLA-4 excretion in MCD and control subjects Urinary CTLA-4 excretion was higher in MCD patients in relapse (458±652 ng/g creatinine) than in MCD patients in remission (142±302 ng/g creatinine) (p=0.01) and control subjects (14.2±22 ng/g creatinine) (p=0.03) (Fig. 1a) . When urinary excretion of CD80 and CTLA-4 were evaluated in the same patients in relapse and in remission, CD80 had decreased significantly in all patients at the time of remission, but CTLA-4
either decreased or remained unchanged in all but five of the 25 patients (Fig. 2a) . These five patients, however, showed an increase in urinary CTLA-4 excretion with remission (Fig. 2a) . There was no significant correlation between urinary CTLA-4 excretion and proteinuria in MCD patients at the time of relapse (p=0.07) (Fig. 2b) . Urinary CTLA-4 excretion was similar in those patients with urine samples obtained at the time of resolution of the proteinuria but still showing low serum albumin and those who presented with no proteinuria and a normal serum albumin (p=0.5) (Fig. 2c) . Urinary CTLA-4 of patients in relapse was analyzed according to time to achieve remission. Although those who responded earlier (< 2 weeks) showed a higher CTLA urinary excretion when compared to those who took>2 weeks to respond, the difference was not statistically significant between the groups (p=0.9). We observed no significant differences in the urinary CTLA-4 excretion among patients who were not receiving any treatment and those treated either with steroids and/or calcineurin inhibitors either at the time of relapse or at the time of remission (p=0.4). The excretion of urinary CTLA-4 in MCD patients in relapse was not significantly different among patients with different patterns of response (infrequent relapse, frequent relapse and steroiddependent) (p=0.8). We examined the ratio of urinary CD80 to CTLA-4 in MCD patients in relapse and in remission and found that the urinary CD80:CTLA-4 ratio was elevated in MCD in relapse when compared to those in remission (p=0.007) (Fig. 3a) . No inverse correlation was observed between urinary CD80 and urinary CTLA-4 in MCD patients at the time of relapse (p=0.06) (Fig. 3b) nor remission (p=0.7) (Fig. 3c) .
Discussion
In this study we evaluated the relationship of urinary CD80 and CTLA-4 excretion in MCD subjects in relapse and remission to test the hypothesis that intrarenal CTLA-4 fails to block podocyte CD80 expression, resulting in the persistently elevated CD80 urinary excretion observed in MCD patients in relapse. We studied the urinary excretion of CD80 and CTLA-4 as their most likely source is the glomerulus. We investigated a different set of MCD patients from those in our previous study [6] , with similar results: a significantly elevated urinary CD80 excretion in MCD patients in relapse compared to those in remission.
CD80, a transmembrane protein, is present in dendritic cells, podocytes, renal tubular cells, and B cells [13, 14] . The source of the increased urinary CD80 in MCD patients in relapse is the podocyte. This argument is supported by several observations: (1) the serum level of sCD80 is similar in patients with MCD during relapse and those in remission, thereby excluding the possibility of oversecretion of circulating CD80 by extra-renal dendritic cells [6] ; (2) immunofluorescence studies in MCD patients in relapse revealed that CD80 localizes exclusively in the podocyte [5] ; (3) the molecular weight of the CD80 measured in urine is 53 KDa, consistent with it being the cell-membrane associated CD80, in contrast to soluble CD80 (23 KDa) which represents the extracellular portion of the molecule [5] .
CD80 may play a critical role in the development of proteinuria in nephrotic syndrome, including MCD [15] . The proposed role of CD80 is based on the lipopolysaccharide (LPS) model of nephrotic syndrome in mice, in which CD80 was de novo expressed on podocytes in association with proteinuria and effacement of foot processes. Importantly, in the study of Reiser et al. [15] , no proteinuria was observed when CD80 knock-out mice were administered LPS.
CTLA-4, a surface protein expressed by T cells, downregulates T cell activation after binding to CD80 on the antigen-presenting cells [8] . The most likely source of urinary CTLA-4 in MCD patients is the podocyte, as demonstrated in our earlier study in which there was no difference in serum CTLA-4 in patients with MCD in relapse and those in remission [6] . Therefore, we propose that the increased urinary CTLA-4 is not due to filtered circulating CTLA-4. Furthermore, cultured human podocytes exposed to Poly:IC have been shown to express CTLA-4 [7] . In addition, there is no evidence of tubular CTLA-4 expression.
We have hypothesized that the persistent CD80 podocyte expression and increased urinary CD80 excretion observed in MCD patients in relapse is due to an impaired podocyte CTLA-4 response which is unable to censor the CD80 expression in the podocyte [9] . Since CTLA-4 is the natural inhibitor of CD80 and increased CD80 podocyte expression may induce proteinuria, one might speculate that the urinary levels of CTLA-4 should increase during relapse, thereby reflecting the increased intrarenal CTLA-4 production regulating the augmented CD80 podocyte expression.
In this study, seven of 30 patients with MCD in relapse were found to have a normal urinary excretion of CTLA-4, with four of these patients having a higher urinary CTLA-4 excretion once remission was achieved. In 23 of the 30 patients with MCD, urinary CTLA-4 excretion was increased during relapse. Urine specimens were available during remission in 17 of these 23 patients, and all but one were found to have lower urinary CTLA-4 excretion after achieving remission compared to relapse. In one patient, the urinary CTLA-4 excretion increased further once remission was achieved.
The excretion of urinary CD80 remained elevated despite increased urinary CTLA-4, as indicated by the CD80:CTLA-4 ratio, a finding similarly reported by us in a smaller number of patients [6] . In the present study, the CD80:CTLA-4 was≤1,in nine of the 30 patients in relapse, but CD80 was rather elevated and proteinuria was present. This observation suggests that the CTLA-4 response, while present during relapse, was inadequate to downregulate CD80 podocyte expression. It can be argued that there was insufficient time for the podocyte to have increased CTLA-4 expression at the time the urine samples were collected. However, CTLA-4 expression was also low during early remission (urine samples taken when proteinuria had resolved but serum albumin was still low) and similarly in late remission (no proteinuria with normalization of serum albumin). Indeed, it may be speculated that the inability of urinary CTLA-4 levels to increase to sufficiently high levels during relapse explains the low spontaneous remission rate of <10% in MCD patients.
Almost all patients were receiving some type of immunosuppressive therapy at the time of relapse. Two drugs are known to influence CTLA-4 expression. Calcineurin agents have been found to decrease CTLA-4 expression in T cells [16] , but the blunted CTLA-4 during relapse in that study could not be attributed to the effect of calcineurin agents because there was no difference in CTLA-4 urinary excretion in patients in relapse when patients on prednisone were compared with those receiving both prednisone and tacrolimus. Therefore, the blunted CTLA-4 expression we observed in MCD patients in remission cannot be due to prednisone effect because steroids have been reported to increase CTLA-4 expression [16] .
Many single nucleotide polymorphisms have been identified in the CTLA-4 gene. The +49GG genotype has been associated with decreased expression of CTLA-4 [17] . The replacement of threonine by alanine has been thought to induce a conformational change of the CTLA-4 protein, leading to an insufficient transport of the molecule to the cell surface. The observation of a higher ratio of cell surface:total CTLA-4Thr versus CTLA-4 Alan confirms this notion [17] . Of interest in our discussion, the frequency of the +49GG genotype is significantly increased in MCD patients with respect to normal controls [17] .
In conclusion, among our study cohort CTLA-4 levels in the urine did not correlate with urinary CD80 excretion, suggesting the possibility that the CTLA4 response to the observed augmented CD80 podocyte expression may be suboptimal in this disease during relapse.
Chimeric CTLA-4 is commercially available. The above findings are the background to justify the administration of the drug to MCD patients in relapse. Well-designed studies need to be performed before CTLA4-immunoglobulin (Ig) can be added to the arsenal of drugs available to treat MCD patients. CTLA4-Ig has been widely used in patients with rheumatoid arthritis with an optimal safety profile [18] .
The administration of CTLA-4 with resolution of the proteinuria could have two important consequences. First, it may become accepted clinical therapy for treating the MCD patient presenting severe steroid dependency or resistance. Second, its clinical use may also confirm that in MCD patients, the mechanism of the proteinuria is due to an increased and uncontrolled podocyte expression of CD80 triggered by a yet to be discovered circulating factor.
